Abstract:You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-Surgical Therapy1 Apr 2015PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY Ding Xu, Jie Ding, and Jun Qi Ding XuDing Xu More articles by this author , Jie DingJie Ding More articles by this author , and Jun QiJun Qi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1285AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Some articles reported that PSA were reduced by approximately 50% after several months of treatment. However£a study from Korea found that PSA decreased by only about 36% after 1-year finasteride taking. The aim of our study was to evaluate the effect of finasteride on PSA in Chinese population. METHODS From Feb 2011 to Jan 2012, 83 BPH patients were enrolled in our study. All the patients were older than 50 years old and all of them received combined therapy (finasteride+doxazosin ). If PSA was greater than 4 ng/ml, a prostate biopsy is required to confirm whether it was benign or not. The patients with age less than 50, other drugs therapy, AUR history, prostate cancer, diabetes, acute prostatitis, history of baldder or prostate surgery were excluded from the study. All the patients were required for 1-year follow-up. PSA level and TPV was measured at the start, 6 months and 12 months, respectively. RESULTS 79 patients completed the follow up. The mean baseline PSA, PSA at 6 months and PSA at 12 months was 3.40ng/ml,1.89ng/ml and 1.87ng/ml, respectively. PSA level reduced by approximately 40% during finasteride therapy. We defined baseline PSA as PSA1, PSA at 6 months as PSA2, PSA at 12 months as PSA3. PSA1 was significantly correlated with PSA2/PSA1 and PSA3/PSA1. The higher the PSA1, the greater PSA2/PSA1 and PSA3/PSA1. However, prostate volume was not correlated with PSA1. We divided the patients into 3 groups according to PSA level. group1, 2, 3 represented the patients with PSA less than 2 ng/ml, between 2 and 4 ng/ml and greater than 4 ng/ml, respectively. Both the PSA2/PSA1 and the PSA3/PSA1 had significant difference among 3 groups. Furthermore, group 1 and group 2 both showed the farily large data variance. CONCLUSIONS When baseline PSA >4ng/ml, decreasing PSA level by approximately 50%. In such cases, doubled PSA could be used for screening. While when baseline PSA ¡Ü4ng/ml£Double PSA might not be an accurate predictor, because on one hand, PSA level deceased by only 30-40%; on the other hand, great variance in data might also affect the accuracy of prediction. Table 2. The effect of finasteride on PSA in different PSA level PSA2/PSA1 P value PSA3/PSA1 P value group 1(PSA1<2ng/ml) (n=28) 0.7100±18.99% <0.001 0.7633±33.38% <0.001 group 2(2≤PSA1<4ng/ml) (n=26) 0.5596±13.41% 0.5658±15.75% group 3(PSA1≥4ng/ml) (n=25) 0.5368±6.76% 0.5137±8.71% PSA1: PSA at baseline; PSA2: PSA at 6 months; PSA3: PSA at 12 months Table 1. Correlation among baseline PSA and other parameters r value P value PSA1 PSA2/PSA1 -0.541 <0.001 PSA1 PSA3/PSA1 -0.492 <0.001 PSA1 TPV1 0.158 0.164 PSA1 TPV2/TPV1 0.071 0.537 PSA1 TPV3/TPV1 0.061 0.591 PSA1: PSA at baseline; PSA2: PSA at 6 months; PSA3: PSA at 12 months © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e330 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ding Xu More articles by this author Jie Ding More articles by this author Jun Qi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Effect of Yunnan Baiyao Therapy on Non-Specific Elevated PSA and Prostate Biopsy

Multivariate study of factors affecting the results of prostate biopsy in PSA grey zone

[The Effect of Yunnan Baiyao on Reduction of Intra-Operative Bleeding of the Patients Undergoing Transurethral Resection of Prostate].

Adjuvant Hormone Therapy after Radical Prostatectomy in High-Risk Localized and Locally Advanced Prostate Cancer: First Multicenter, Observational Study in China

Clinical Effect Study of Serum PSA Level and Digital Rectal Examination in Guiding the Prostate Biopsy

Effect of yunnan baiyao capsules on hemorrhage condition, inflammatory response and stress response after percutaneous lung biopsy

[Compound Ciprofloxacin Suppository Combined with Ningbitai and Yunnan Baiyao for Histological Prostatitis with PSA Elevation].

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

Study On The Diagnostic Value Of Various Volume-Adjusted Psa Derivatives In Prostate Cancer In South Chinese Populations

Phytotherapy Might Have a Role in Reducing Unnecessary Prostate Biopsies: Results from an Exploratory, Randomized Controlled Trial of Two Different Phytotherapeutic Agents

Yunnan Baiyao Adjuvant Treatment for Patients with Hemoptysis: A Systematic Review and Meta-Analysis

Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011.

Analysis of the pathological characteristics after biopsy and surgery in BPH patients with abnormal serum PSA level

Effects of Psychological Intervention on Perioperative Quality of Life and Serum PSA and FPSA Levels of Patients with Prostate Cancer Treated with Integrated Traditional Chinese and Western Medicine

Percent Free Prostate-Specific Antigen Is Effective To Predict Prostate Biopsy Outcome In Chinese Men With Prostate-Specific Antigen Between 10.1 And 20.0 Ng Ml(1)

Diagnostic value of transrectal ultrasound-guided saturation prostate biopsy after initial negative result

Results of serial transcrectal ultrasound guided biopsy in prostate cancer screening study(report of 45 cases)

The clinical analysis on endocrine therapy of late prostate carcinoma

Clinical Efficacy of TKRP Surgery and Its Effect on Serum PSA Level for Treating the Patients with Benign Prostatic Hyperplasia

Effect of Combining Traditional Chinese Medicine with Hormonal Therapy on Quality of Life and Tumor Markers of Prostate Cancer Patients

PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY